Platforms for Manufacturing Allogeneic, Autologous and iPSC Cell Therapy Products: An Industry Perspective

• Published in: Advances in biochemical engineering, biotechnology Vol. 165; p. 323
• Main Authors: Abraham, Eytan, Ahmadian, Behnam Baghbaderani, Holderness, Kathryn, Levinson, Yonatan, McAfee, Erika
• Format: Journal Article
• Language: English
• Published: Germany 01.01.2018
• Subjects: Allogeneic; Autologous; iPSCs; Cell therapy; CAR-T; Mesenchymal stem cells
• DOI: 10.1007/10_2017_14
• ISSN: 0724-6145

As cell therapy processes mature from benchtop research protocols to industrial processes capable of manufacturing market-relevant numbers of doses, new cell manufacturing platforms are required. Here we give an overview of the platforms and technologies currently available to manufacture allogeneic cell products, such as mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs), and technologies for mass production of autologous cell therapies via scale-out. These technologies include bioreactors, microcarriers, cell separation and cryopreservation equipment, molecular biology tools for iPSC generation, and single-use controlled-environment systems for autologous cell production. These platforms address the challenges of manufacturing cell products in greater numbers while maintaining process robustness and product quality.